FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Can Vet J / Outcome of horses with enterocolitis receiving oncotic fluid...
The Canadian veterinary journal = La revue veterinaire canadienne2019; 60(11); 1207-1212;

Outcome of horses with enterocolitis receiving oncotic fluid support with either plasma or hetastarch.

Abstract: The objective of this study was to determine whether there was an association between type of colloid administered and survival of horses with enterocolitis (N = 92). A retrospective review of medical records of horses with enterocolitis treated with plasma or hetastarch (HES) between January 1, 2005 and December 31, 2011 was performed. Data collected included signalment, outcome, physical and clinicopathologic findings, and volume and type of colloid administered. Sixty-nine horses (75%) were treated with plasma and 23 horses (25%) were treated with HES. After accounting for confounding variables, horses treated with plasma (80% survival) were more likely to survive to discharge than horses treated with HES (47% survival; P = 0.041) despite similar disease severity at admission. This study provides support that use of natural colloids may be superior to treatment with synthetic colloids in horses with enterocolitis. A prospective, multi-center trial comparing outcome of critically ill equine patients treated with natural or synthetic colloids is warranted. Issue des chevaux avec entérocolite recevant un traitement de support par fluide oncotique avec soit du plasma ou de l’héta-amidon. L’objectif de la présente étude était de déterminer s’il y avait une association entre le type de colloïde administré et la survie de chevaux avec entérocolite (N = 92). Une revue rétrospective des dossiers médicaux de chevaux avec entérocolite traités avec du plasma ou de l’héta-amidon (HES) entre le 1er janvier 2005 et le 31 décembre 2011 fut effectuée. Les données amassées incluaient l’anamnèse, l’issue, les trouvailles physiques et clinico-pathologiques, ainsi que le volume et le type de colloïde administré. Soixante-neuf chevaux (75 %) furent traités avec du plasma et 23 chevaux (25 %) furent traités avec du HES. Après avoir pris en considération les variables confondantes, les chevaux traités avec le plasma (80 % de survie) étaient plus susceptibles de survivre jusqu’au congé que les chevaux traités avec HES (47 % de taux de survie; P = 0,041) malgré la similarité de la sévérité de la condition lors de l’admission. Cette étude fournie des arguments que l’utilisation de colloïdes naturels serait supérieure au traitement avec des colloïdes synthétiques chez des chevaux avec entérocolite. Une étude prospective, multicentres comparant l’issue de patients équins sévèrement malades traités avec des colloïdes naturels ou synthétiques est requise.(Traduit par Dr Serge Messier).
Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.
Get Full Text
Publication Date: 2019-11-07 PubMed ID: 31692633PubMed Central: PMC6805053
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Multicenter Study

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research aimed to establish a link between the type of colloid treatment administered and survival rates in horses suffering from enterocolitis. The findings suggest that horses treated with natural plasma rather than synthetic hetastarch are significantly more likely to survive, despite the severity of the disease at the point of admission.

Study Methodology

  • The study was based on a retrospective review of medical records of horses diagnosed with enterocolitis and treated with either plasma or hetastarch (HES) from January 1, 2005, to December 31, 2011.
  • The data collected from the records included the horse’s signalment (a brief description of the horse such as age, breed, sex, color, etc.), outcome of the treatment, findings from physical and clinicopathologic tests, and details about the volume and type of colloid administered.

Results and Findings

  • Of the total 92 horses in the study, 75% (69 horses) were treated with plasma, and 25% (23 horses) were treated with HES.
  • The study found that horses treated with plasma had a survival rate of 80%. At the same time, those treated with HES had a significantly lower survival rate of 47%.
  • This difference in survival rates remained even after accounting for confounding variables, indicating the type of colloid treatment could be a major determinant of the outcome.
  • Importantly, the severity of the disease at admission was similar among horses treated with either plasma or HES.

Conclusions and Implications

  • Based on the findings, the study suggests that treatment with natural colloids (or plasma) could be superior to treatment with synthetic colloids like HES for horses with enterocolitis.
  • Given the significant potential impacts on survival rates, the research concludes that a prospective, multi-center trial comparing critically ill equine patients treated with natural or synthetic colloids is warranted.

Cite This Article

APA
Kopper JJ, Kogan CJ, Cook VL, Schott HC. (2019). Outcome of horses with enterocolitis receiving oncotic fluid support with either plasma or hetastarch. Can Vet J, 60(11), 1207-1212.

Publication

The Canadian veterinary journal = La revue veterinaire canadienne
ISSN: 0008-5286
NlmUniqueID: 0004653
Country: Canada
Language: English
Volume: 60
Issue: 11
Pages: 1207-1212

Researcher Affiliations

Kopper, Jamie J
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA (Kopper, Cook, Schott II); Center for Interdisciplinary Statistical Education and Research, Washington State University, Pullman, Washington, USA (Kogan).
Kogan, Clark J
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA (Kopper, Cook, Schott II); Center for Interdisciplinary Statistical Education and Research, Washington State University, Pullman, Washington, USA (Kogan).
Cook, Vanessa L
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA (Kopper, Cook, Schott II); Center for Interdisciplinary Statistical Education and Research, Washington State University, Pullman, Washington, USA (Kogan).
Schott, Harold C
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA (Kopper, Cook, Schott II); Center for Interdisciplinary Statistical Education and Research, Washington State University, Pullman, Washington, USA (Kogan).

MeSH Terms

  • Animals
  • Colloids
  • Enterocolitis / veterinary
  • Horse Diseases
  • Horses
  • Hydroxyethyl Starch Derivatives
  • Plasma
  • Prospective Studies
  • Retrospective Studies

References

This article includes 37 references
  1. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: An improved paradigm for prescribing intravenous fluid therapy.. Br J Anaesth 2012;108:384–394.
    pubmed: 22290457
  2. McIlroy DR, Kharasch ED. Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia.. Anesth Analg 2003;96:1572–1577.
    pubmed: 12760977
  3. Pantaleon LG. Fluid therapy in equine patients: Small-volume fluid resuscitation.. Compendium Contin Educ Vet 2010;32:E1–6. quiz E7.
    pubmed: 21308662
  4. Dolente BA, Wilkins PA, Boston RC. Clinicopathologic evidence of disseminated intravascular coagulation in horses with acute colitis.. J Am Vet Med Assoc 2002;220:1034–1038.
    pubmed: 12420783
  5. Gratwick Z, Viljoen A, Page PC, Goddard A, Fosgate GT, Lyle CH. A comparison of the effects of a 4% modified fluid gelatin and a 6% hydroxyethyl starch on haemodilution, colloid osmotic pressure, haemostasis and renal parameters in healthy ponies.. Equine Vet J 2017;49:363–368.
    pubmed: 27258662
  6. Jones PA, Tomasic M, Gentry PA. Oncotic, hemodilutional, and hemostatic effects of isotonic saline and hydroxyethyl starch solutions in clinically normal ponies.. Am J Vet Res 1997;58:541–548.
    pubmed: 9140565
  7. Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: Effects on kidney function.. Cochrane Database Syst Rev 2013;7:Cd007594.
    pmc: PMC11561698pubmed: 23881659
  8. Zarychanski R, Abou-Setta AM, Turgeon AF. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: A systematic review and meta-analysis.. JAMA 2013;309:678–688.
    pubmed: 23423413
  9. Hayes G, Benedicenti L, Mathews K. Retrospective cohort study on the incidence of acute kidney injury and death following hydroxyethyl starch (HES 10% 250/0.5/5:1) administration in dogs (2007–2010). J Vet Emerg Crit Care 2016;26:35–40.
    pubmed: 26587795
  10. Blong AE, Epstein KL, Brainard BM. In vitro effects of three formulations of hydroxyethyl starch solutions on coagulation and platelet function in horses.. Am J Vet Res 2013;74:712–720.
    pubmed: 23627384
  11. Epstein KL, Bergren A, Giguère S, Brainard BM. Cardiovascular, colloid osmotic pressure, and hemostatic effects of 2 formulations of hydroxyethyl starch in healthy horses.. J Vet Intern Med 2014;28:223–233.
    pmc: PMC4895541pubmed: 24428324
  12. Reuteler A, Axiak-Flammer S, Howard J, Adamik KN. Comparison of the effects of a balanced crystalloid-based and a saline-based tetrastarch solution on canine whole blood coagulation and platelet function.. J Vet Emerg Crit Care 2017;27:23–34.
    pubmed: 27926787
  13. lbrecht NA, Howard J, Kovacevic A, Adamik KN. In vitro effects of 6% hydroxyethyl starch 130/0.42 solution on feline whole blood coagulation measured by rotational thromboelastometry.. BMC Vet Res 2016;12:155.
    pmc: PMC4962524pubmed: 27459858
  14. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch.. Thromb Haemost 1997;78:974–983.
    pubmed: 9308738
  15. Wilson EM, Holcombe SJ, Lamar A, Hauptman JG, Brooks MB. Incidence of transfusion reactions and retention of procoagulant and anticoagulant factor activities in equine plasma.. J Vet Intern Med 2009;23:323–328.
    pubmed: 19192141
  16. D’Agostino RB. Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.. Stat Med 1998;17:2265–2281.
    pubmed: 9802183
  17. Radcliffe RM, Divers TJ, Fletcher DJ, Mohammed H, Kraus MS. Evaluation of L-lactate and cardiac troponin I in horses undergoing emergency abdominal surgery.. J Vet Emerg Crit Care 2012;22:313–319.
    pubmed: 22702437
  18. McConachie E, Giguère S, Barton MH. Scoring system for multiple organ dysfunction in adult horses with acute surgical gastrointestinal disease.. J Vet Intern Med 2016;30:1276–1283.
    pmc: PMC5094519pubmed: 27296454
  19. Ihler CF, Venger JL, Skjerve E. Evaluation of clinical and laboratory variables as prognostic indicators in hospitalized gastrointestinal colic horses.. Acta Vet Scand 2004;45:109–118.
    pmc: PMC1820986pubmed: 15535091
  20. Puotunen-Reinert A. Study of variables commonly used in examination of equine colic cases to assess prognostic value.. Equine Vet J 1986;18:275–277.
    pubmed: 3758004
  21. Staempfli HR, Townsend HG, Prescott JF. Prognostic features and clinical presentation of acute idiopathic enterocolitis in horses.. Can Vet J 1991;32:232–237.
    pmc: PMC1481315pubmed: 17423769
  22. Stewart MC, Hodgson JL, Kim H, Hutchins DR, Hodgson DR. Acute febrile diarrhoea in horses: 86 cases (1986–1991). Aust Vet J 1995;72:41–44.
    pubmed: 7779031
  23. Cohen ND, Woods AM. Characteristics and risk factors for failure of horses with acute diarrhea to survive: 122 cases (1990–1996). J Am Vet Med Assoc 1999;214:382–390.
    pubmed: 10023402
  24. Artigas A, Wernerman J, Arroyo V, Vincent JL, Levy M. Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis.. J Crit Care 2016;33:62–70.
    pubmed: 26831575
  25. Vincent JL. Relevance of albumin in modern critical care medicine.. Best Pract Res Clin Anaesthesiol 2009;23:183–191.
    pubmed: 19653438
  26. Fleck A, Raines G, Hawker F. Increased vascular permeability: A major cause of hypoalbuminaemia in disease and injury.. Lancet 1985;1:781–784.
    pubmed: 2858667
  27. Reeves RB. Temperature-induced changes in blood acid-base status: Donnan rCl and red cell volume.. J Appl Physiol 1976;40:762–767.
    pubmed: 6425
  28. Quinlan GJ, Margarson MP, Mumby S, Evans TW, Gutteridge JM. Administration of albumin to patients with sepsis syndrome: A possible beneficial role in plasma thiol repletion.. Clin Sci 1998;95:459–465.
    pubmed: 9748422
  29. Jurgens G, Müller M, Garidel P. Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A.. J Endotoxin Res 2002;8:115–126.
    pubmed: 12028751
  30. McKenzie EC, Esser MM, McNitt SE, Payton ME. Effect of infusion of equine plasma or 6% hydroxyethyl starch (600/0.75) solution on plasma colloid osmotic pressure in healthy horses.. Am J Vet Res 2016;77:708–714.
    pubmed: 27347823
  31. Guidet B, Martinet O, Boulain T. Assessment of hemodynamic efficacy and safety of 6% hydroxyethyl starch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study.. Crit Care 2012;16:R94.
    pmc: PMC3580640pubmed: 22624531
  32. Glover PA, Rudloff E, Kirby R. Hydroxyethyl starch: A review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use.. J Vet Emerg Crit Care 2014;24:642–661.
    pubmed: 25158892
  33. Caironi P, Tognoni G, Masson S. Albumin replacement in patients with severe sepsis or septic shock.. N Engl J Med 2014;370:1412–1421.
    pubmed: 24635772
  34. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit.. N Engl J Med 2004;350:2247–2256.
    pubmed: 15163774
  35. Jiang L, Jiang S, Zhang M, Zheng Z, Ma Y. Albumin versus other fluids for fluid resuscitation in patients with sepsis: A meta-analysis.. PloS One 2014;9:e114666.
    pmc: PMC4256427pubmed: 25474401
  36. . HESPAN® (6% hetastarch in 0.9% sodium chloride injection) B. Braun Medical; Mar, 2003.. .
  37. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies.. Multivariate Behav Res 2011;46:399–424.
    pmc: PMC3144483pubmed: 21818162

Citations

This article has been cited 3 times.
  1. Hardefeldt L, Thomas K, Page S, Norris J, Browning G, El Hage C, Stewart A, Gilkerson J, Muscatello G, Verwilghen D, van Galen G, Bauquier J, Cuming R, Reynolds B, Whittaker C, Wilkes E, Clulow J, Burden C, Begg L. Antimicrobial prescribing guidelines for horses in Australia. Aust Vet J 2025 Dec;103(12):781-889.
    doi: 10.1111/avj.70003pubmed: 40903020google scholar: lookup
  2. Gomez DE, Kopper JJ, Byrne DP, Renaud DL, Schoster A, Dunkel B, Arroyo LG, Mykkanen A, Gilsenan WF, Pihl TH, Lopez-Navarro G, Tennent-Brown BS, Hostnik LD, Mora-Pereira M, Marques F, Gold JR, DeNotta SL, Desjardins I, Stewart AJ, Kuroda T, Schaefer E, Oliver-Espinosa OJ, Agne GF, Uberti B, Veiras P, Delph Miller KM, Gialleti R, John E, Toribio RE. Treatment approaches to horses with acute diarrhea admitted to referral institutions: A multicenter retrospective study. PLoS One 2024;19(11):e0313783.
    doi: 10.1371/journal.pone.0313783pubmed: 39565809google scholar: lookup
  3. Crabtree NE, Epstein KL. Current Concepts in Fluid Therapy in Horses. Front Vet Sci 2021;8:648774.
    doi: 10.3389/fvets.2021.648774pubmed: 33855057google scholar: lookup
Subscribe to our newsletter
Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.